Developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need

About Spruce Biosciences

Spruce is committed to transforming the lives of patients living with rare endocrine disorders. Spruce’s wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage clinical trials in adult patients with classic congenital adrenal hyperplasia (CAH).

Learn More

Challenges of Classic CAH Treatment

Patients and physicians are faced with the difficult choice between the detrimental effects of chronically high adrenal androgen levels or excessive doses of glucocorticoids. This dilemma has persisted for approximately 50 years.

Detrimental effects of chronically high adrenal androgen levels
or
Harmful consequences of excessive, lifelong glucocorticoid use

Learn More

News